Aberrant FICD-mediated AMPylation drives α-Synuclein pathology and overall protein dyshomeostasis in dopaminergic neurons in Parkinson's disease

This study identifies that aberrant upregulation and hyperactivation of FICD-mediated AMPylation in dopaminergic neurons drive Parkinson's disease pathology by disrupting protein homeostasis, impairing lysosomal function, and promoting α-synuclein aggregation, while demonstrating that pharmacological inhibition of this pathway can reverse these detrimental effects.

The Gist

The Big Picture: A Broken Factory in the Brain

Imagine your brain cells are like busy factories. Their job is to build, maintain, and recycle thousands of different parts to keep the factory running smoothly. In a healthy factory, there is a strict quality control system. If a part is broken or a machine is clogged, the factory cleans it up immediately.

In Parkinson's Disease, this factory starts to break down. A specific protein called alpha-synuclein (let's call it "The Glue") starts sticking together in clumps. These clumps clog the machinery, stop the factory from working, and eventually cause the factory to shut down (cell death).

This study asks a big question: What is causing the factory to get clogged in the first place?

The researchers found a "supervisor" protein called FICD. In a healthy factory, FICD is a helpful manager that checks the quality of the machines. But in Parkinson's, this manager goes crazy. It starts overworking, tagging too many things, and accidentally breaking the very systems meant to clean up the mess.

---

The Story in Three Acts

Act 1: The Overworked Supervisor (FICD)

The researchers discovered that FICD is a special manager that lives in the "Endoplasmic Reticulum" (the factory's assembly line). Its job is to attach a tiny "tag" (called AMPylation) to other proteins. Think of this tag like a sticky note that tells a protein what to do or where to go.

• The Problem: In Parkinson's patients, the factory is under stress. The researchers found that the FICD manager is overworked and hyperactive. It is putting sticky notes on everything, even things that shouldn't be tagged.
• The Target: FICD loves to tag the trash collectors (lysosomal proteins). Imagine if the supervisor started putting "Do Not Touch" sticky notes on the janitors. The janitors can't do their job, so the trash (broken proteins) piles up.

Act 2: The Vicious Cycle

Here is where it gets tricky. The study found a two-way street of destruction:

1. The Glue makes the Manager crazy: When "The Glue" (alpha-synuclein) starts clumping, it stresses the factory. This stress makes the FICD manager go into overdrive, tagging even more trash collectors.
2. The Manager makes the Glue worse: Because the FICD manager is tagging the trash collectors, the factory can't clean up "The Glue." The clumps get bigger, the factory gets more stressed, and the manager goes even crazier.

It's like a feedback loop: The mess makes the manager panic, and the panicked manager makes the mess worse.

Act 3: The "Do Not Disturb" Sign

The researchers also found that this overactive manager is specifically targeting the dopamine-producing neurons (the workers who make the chemical that helps us move). These workers are the first to get overwhelmed and die.

However, there is good news! The researchers tested a "pause button" called Closantel (a drug originally used for sheep parasites, but repurposed here).

• The Experiment: They gave Closantel to the sick factory workers (human neurons grown in a lab).
• The Result: The drug stopped the FICD manager from putting those bad sticky notes on the trash collectors.
  • The trash collectors started working again.
  • The "Glue" clumps started to dissolve.
  • The workers' long arms (neurites), which had shriveled up, started to grow back healthy.

---

Key Takeaways in Everyday Terms

1. The Culprit isn't just the Glue: For a long time, we thought Parkinson's was just about the "Glue" (alpha-synuclein) clumping up. This study shows that a broken management system (FICD) is a major driver of the problem.
2. The Trash Collectors are Sabotaged: The disease works by disabling the cell's natural cleaning crew. If you can't clean the trash, the factory collapses.
3. The "Switch" is Reversible: The most exciting part is that when they turned off the overactive manager (using the drug Closantel), the cells started to heal. The clumps went away, and the neurons looked healthier.

The Bottom Line

This paper suggests that Parkinson's isn't just about a bad protein; it's about a broken communication system inside the cell. The cell's "manager" (FICD) gets confused and stops the "janitors" from cleaning up.

By finding a way to calm down this overactive manager, scientists might be able to stop the brain cells from dying and potentially treat Parkinson's disease. It's like fixing the factory's management software so the janitors can get back to work and clear out the mess.

Technical Summary

1. Problem Statement

Parkinson's disease (PD) is characterized by the progressive loss of dopaminergic neurons in the substantia nigra and the accumulation of aggregated $\alpha$-synuclein (aSyn) in Lewy bodies. While protein dyshomeostasis is a known driver of PD, the specific molecular mechanisms linking post-translational modifications (PTMs) to this pathology remain unclear.

• The Gap: Filamentation induced by cAMP domain-containing protein (FICD) is an endoplasmic reticulum (ER)-resident enzyme that catalyzes AMPylation (the addition of AMP to proteins). While FICD is known to regulate the Unfolded Protein Response (UPR) via its substrate BiP, its role in PD and aSyn aggregation was previously undefined.
• The Hypothesis: The authors hypothesized that dysregulated FICD-mediated AMPylation contributes to PD pathogenesis by disrupting protein homeostasis, specifically affecting the ER-lysosome axis and promoting aSyn aggregation.

2. Methodology

The study employed a multi-modal approach combining human post-mortem tissue, patient-derived cell models, transgenic mice, and advanced proteomics.

• Human Models:
  • hiPSC-derived Neurons: Differentiation of midbrain dopaminergic neurons from a PD patient with an SNCA gene duplication (SNCADupl) and an isogenic CRISPR-Cas9 corrected control (SNCACtrl).
  • Post-mortem Tissue: Analysis of substantia nigra and putamen from PD patients and controls (using immunohistochemistry and Western blot).
• Animal Models:
  • Transgenic mice overexpressing human aSyn under the Thy1 promoter (Thy1-aSyn, modeling PD) and MBP promoter (MBP-aSyn, modeling Multiple System Atrophy).
  • Wild-type rats for baseline FICD distribution analysis.
• Cell Models:
  • H4 neuroglioma cells stably overexpressing human aSyn (H4-aSyn) and control cells (H4-Ctrl).
  • Transfection with FICD variants: Wild-type (WT), constitutively active (E234G), and catalytically inactive (H363A).
• Pharmacological Intervention: Treatment with closantel, a small-molecule inhibitor of FICD-mediated AMPylation.
• Proteomic & Analytical Techniques:
  • Chemical Proteomics: Use of the metabolically activatable adenosine analog pro-N6pA to label, enrich, and identify AMPylated proteins via LC-MS/MS (Data-Dependent and Data-Independent Acquisition).
  • SILAC (Stable Isotope Labeling with Amino acids in Cell Culture): Pulse-chase experiments to measure global protein turnover rates and half-lives.
  • Functional Assays: Cathepsin B/D activity assays, solubility assays, filter trap assays for aSyn aggregation, flow cytometry for apoptosis, and immunocytochemistry for neurite morphology.

3. Key Contributions & Findings

A. FICD Expression and Selective Vulnerability

• Preferential Expression: FICD is highly expressed in dopaminergic neurons (TH+) in both human and rodent substantia nigra.
• Pathological Upregulation: FICD levels are significantly elevated in the basal ganglia of PD patients and synucleinopathy mouse models.
• Selective Loss: Despite overall upregulation, there is a reduced proportion of FICD-expressing dopaminergic neurons in PD brains and SNCADupl-derived neurons. This suggests that dopaminergic neurons are selectively vulnerable to FICD-mediated stress, leading to their death, while non-dopaminergic FICD+ cells survive.

B. Mechanism: AMPylation Targets Lysosomal Proteins

• Proteomic Profiling: Chemical proteomics revealed that FICD hyperactivation leads to a massive remodeling of the AMPylated proteome.
• Lysosomal Signature: The most significantly enriched pathway among AMPylated targets is the lysosomal pathway. Key substrates include Cathepsin B (CTSB), Cathepsin D (CTSD), PLD3, and FTL.
• No Direct aSyn AMPylation: Contrary to previous cell-free reports, aSyn itself was not detected as an AMPylated substrate in cellular models. The pathology is driven by the AMPylation of other proteins that regulate aSyn clearance.

C. Disruption of Protein Homeostasis (ER-Lysosome Axis)

• ER Stress: Hyperactivation of FICD (via the E234G mutant) triggers severe ER stress, evidenced by upregulation of BiP, ATF6, spliced XBP1, and CHOP.
• Lysosomal Dysfunction: Hyper-AMPylation of CTSB impairs its maturation and enzymatic activity. This leads to a global reduction in protein turnover (increased protein half-lives) and accumulation of toxic aggregates.
• Bidirectional Loop: aSyn overexpression upregulates FICD, which in turn causes AMPylation dysregulation, further exacerbating aSyn aggregation and cell death.

D. Therapeutic Intervention

• Pharmacological Inhibition: Treatment with closantel (a FICD inhibitor) in SNCADupl-derived neurons:
  • Reduced BiP AMPylation.
  • Significantly decreased the accumulation of aggregated (phosphorylated) aSyn in neurites.
  • Restored neurite diameter and volume, ameliorating morphological deficits.
  • Did not affect control (SNCACtrl) neurons, indicating specificity to the pathological state.

4. Significance

• Novel Pathogenic Mechanism: The study identifies FICD-mediated AMPylation as a critical molecular switch in PD. It establishes a causal link between FICD hyperactivation, lysosomal dysfunction, and aSyn pathology.
• ER-Lysosome Crosstalk: It highlights a specific mechanism where ER-resident AMPylation dysregulates lysosomal enzyme maturation (specifically CTSB), creating a bottleneck in protein degradation that drives neurodegeneration.
• Therapeutic Target: The findings validate the FICD-AMPylation pathway as a druggable target. The successful reversal of aSyn aggregation and neurite degeneration by closantel in human patient-derived neurons suggests that modulating AMPylation could be a viable strategy to halt or reverse PD progression.
• Selectivity: The observation that dopaminergic neurons are uniquely susceptible to FICD dysregulation provides a molecular explanation for the selective vulnerability of these cells in PD.

Conclusion

This paper demonstrates that aberrant FICD-mediated AMPylation is not merely a bystander but a driver of PD pathology. By hyper-AMPylation of lysosomal proteins, FICD disrupts the ER-lysosome axis, impairs protein turnover, and accelerates aSyn aggregation and neuronal death. Pharmacological inhibition of this pathway offers a promising therapeutic avenue for restoring proteostasis in Parkinson's disease.